Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2019

Share-Based Compensation

Schedule of weighted average assumptions used to estimate fair values of the stock options granted and the estimated annual forfeiture rates used to recognize the associated compensation expense and the weighted average fair value of the options granted

	Nine Months Ended
	March 31, 2019			March 31, 2018
Risk-free interest rate		2.9	%		2.12	%
Expected volatility		58.4	%		57.6	%
Expected dividend yield		—	%		—	%
Forfeiture rate		6.5	%		6.5	%
Expected term (in years)		5.3	years		5.4	years
Weighted average fair value	$	6.52		$	11.25

Summary of stock option award activity

						Weighted
		Weighted-				Average
		Average		Aggregate		Remaining
		Exercise		Intrinsic		Contractual
(In thousands, except for weighted average price and life data)	Awards	Price		Value		Life (yrs.)
Outstanding at June 30, 2018	1,057	$	22.46	$	2,584	5.4
Granted	73	$	12.20
Exercised	(52)	$	4.16	$	237
Forfeited, expired or repurchased	(376)	$	33.57
Outstanding at March 31, 2019	702	$	16.81	$	751	5.0
Vested and expected to vest at March 31, 2019	694	$	16.83	$	751	4.9
Exercisable at March 31, 2019	599	$	17.09	$	751	4.3

Summary of non-vested restricted stock awards

		Weighted
		Average Grant -		Aggregate
(In thousands, except for weighted average price and life data)	Awards	date Fair Value		Intrinsic Value
Non-vested at June 30, 2018	704	$	20.06
Granted	1,176	$	9.90
Vested	(407)	$	20.04	$	3,918
Forfeited	(128)	$	14.00
Non-vested at March 31, 2019	1,345	$	11.76

Schedule of non-vested performance-based shares

		Weighted
		Average Grant -		Aggregate
(In thousands, except for weighted average price and life data)	Awards	date Fair Value		Intrinsic Value
Non-vested at June 30, 2018	20	$	25.58
Granted	52	$	17.69
Vested	—	$	—	$	—
Forfeited	—	$	—
Non-vested at March 31, 2019	72	$	19.92

Schedule of allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
(In thousands)	2019		2018		2019		2018
Selling, general and administrative expenses	$	1,125	$	1,638	$	4,434	$	5,350
Research and development expenses		208		149		608		477
Cost of sales		656		478		1,932		1,191
Total	$	1,989	$	2,265	$	6,974	$	7,018
Tax benefit at statutory rate	$	447	$	668	$	1,569	$	2,070